{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Adjuvant therapy",
      "Borderline resectable pancreatic cancer",
      "Chemotherapy",
      "Locally advanced pancreatic cancer",
      "Neoadjuvant therapy",
      "Preoperative therapy",
      "Resectable pancreatic cancer",
      "Resection"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29191281",
  "DateCompleted": {
    "Year": "2017",
    "Month": "12",
    "Day": "11"
  },
  "DateRevised": {
    "Year": "2017",
    "Month": "12",
    "Day": "11"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.suc.2017.09.009",
      "S0039-6109(17)30145-7"
    ],
    "Journal": {
      "ISSN": "1558-3171",
      "JournalIssue": {
        "Volume": "98",
        "Issue": "1",
        "PubDate": {
          "Year": "2018",
          "Month": "Feb"
        }
      },
      "Title": "The Surgical clinics of North America",
      "ISOAbbreviation": "Surg Clin North Am"
    },
    "ArticleTitle": "Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We?",
    "Pagination": {
      "StartPage": "95",
      "EndPage": "111",
      "MedlinePgn": "95-111"
    },
    "Abstract": {
      "AbstractText": [
        "Since the advent of modern surgery for pancreatic cancer, clinicians have recognized this cancer's propensity to recur locally, metastasize, and cause death. Despite significant efforts to improve patient outcomes with better adjuvant therapy, only modest gains in survival have been observed. An alternative strategy of neoadjuvant therapy followed by surgery has the potential to improve patient selection and survival, and expand the pool of patients eligible for curative surgery. This article summarizes large, randomized trials of adjuvant therapy, explains the limitations imposed by up-front surgery, and suggests neoadjuvant therapy as a rational alternative to initial surgery and adjuvant therapy."
      ],
      "CopyrightInformation": "Copyright \u00a9 2017 Elsevier Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard-Unit 421, Houston, TX 77030, USA. Electronic address: rwolff@mdanderson.org."
          }
        ],
        "LastName": "Wolff",
        "ForeName": "Robert A",
        "Initials": "RA"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Surg Clin North Am",
    "NlmUniqueID": "0074243",
    "ISSNLinking": "0039-6109"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chemotherapy, Adjuvant"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Combined Modality Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoadjuvant Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pancreatectomy"
    },
    {
      "QualifierName": [
        "drug therapy",
        "radiotherapy",
        "surgery"
      ],
      "DescriptorName": "Pancreatic Neoplasms"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Preoperative Care"
    }
  ]
}